Keyword: Ian Read

Pfizer became the center of a drug pricing controversy this summer and delayed dozens of price hikes. Now it's ready to raise prices again in January.

A top pharma CEO says President Trump is right to say other countries benefit from higher U.S. drug prices, but he’s not sold on proposals for a fix.

There's been no shortage of drug pricing talk in recent weeks, and now Merck's and Pfizer's CEOs have had a chance to voice their thoughts.

Integration following a large-scale M&A is too much a distraction from Pfizer's "best pipeline in our history," said Bourla.

Big biopharma CEOs gave most or all their campaign contributions to Republicans this season, but one went full blue with his $120,000.

A week after Pfizer unveiled a reshuffled team that'll report to incoming CEO Albert Bourla, the drug giant says it plans to trim its workforce.

Hours after Pfizer unveiled its CEO succession plan, industry watchers had one key question: Will incoming chief Albert Bourla chase M&A?

After steering Pfizer through nine years of selloffs, spinoffs, reorgs, drug launches, patent losses, dealmaking—and one big deal that didn’t—CEO Ian Read is stepping aside.

What would a world with no drug rebates look like? Pfizer’s Ian Read is already imagining it.

Even before Pfizer faced Trump's wrath for July price hikes, Novartis decided increasing its own prices wouldn’t be prudent, its CEO said Wednesday.